Zebo Jiang

Title: Zebo Jiang: Innovator in Cancer Treatment

Introduction

Zebo Jiang is a notable inventor based in Macao, MO, recognized for his contributions to the field of cancer treatment. He has developed innovative methods aimed at addressing gefitinib-resistant non-small-cell lung cancer (NSCLC). His work is significant in the ongoing battle against cancer, particularly in improving treatment options for patients who do not respond to conventional therapies.

Latest Patents

Zebo Jiang holds a patent for a method for treating gefitinib-resistant non-small-cell lung cancer. This invention involves administering an effective amount of a resveratrol analog, specifically (Z)3,4,5,4'-tetramethoxystilbene (TMS), to patients in need. The patent also describes a method for inducing apoptosis in gefitinib-resistant NSCLC cells by applying the resveratrol analog at an effective concentration. The mechanisms of these methods are mediated by various signaling pathways related to cell proliferation and differentiation, including mTOR, JNK, and certain EGFR phosphorylated tyrosine kinases.

Career Highlights

Zebo Jiang is affiliated with the Macau University of Science and Technology, where he conducts research and develops innovative solutions in the medical field. His work has garnered attention for its potential impact on cancer treatment, particularly for patients facing resistance to existing therapies.

Collaborations

Zebo Jiang collaborates with several colleagues, including Lai-Han Leung and Xing-Xing Fan. These partnerships enhance the research and development process, allowing for a multidisciplinary approach to tackling complex medical challenges.

Conclusion

Zebo Jiang's contributions to cancer treatment through his innovative patent highlight the importance of research in developing effective therapies for resistant forms of cancer. His work at the Macau University of Science and Technology exemplifies the critical role of inventors in advancing medical science and improving patient outcomes.